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1 Drug description 
Generic/Brand name/ATC code:  
Vemurafenib (PLX4032)/ Zelboraf™(USA)/ L01XE15 
Developer/Company:  
Originator: Plexxikon. Licensee: Hoffmann-La Roche 
Description:  
Mutated genes are frequently present in melanomas. One of the most com-
mon one is a mutation in BRAF, a serine-threonine kinase, which can be 
found in about  47% of patients with melanoma [1]. The majority of BRAF 
mutations (i.e. 80%-90%) are V600E mutations, followed by V600K muta-
tions and others [1, 2]. Mutations in this protein have been found not only in 
approximately 50% of melanoma, but in 30-70% of thyroid tumours, in 30% 
of serous low-grade ovarian tumours and in 10% of colorectal cancers [3]. 
PLX4032/Vemurafenib, a kinase which also inhibits the BRAF V600E muta-
tion,  is one in a series of BRAF-kinase inhibitors: Non-selective inhibitors 
are sorafenib and RAF265, selective inhibitors are vemurafenib and 
GSK2118436 [1]. Vemurafenib showed marked selectivity in biochemical 
and cellular assays. Additionally it showed good oral bioavailability and was 
therefore further developed in human trials [4]. Preclinical studies showed 
that PLX4032 and its analogue PLX4720 inhibit the kinase activity of BRAF 
with the V600E mutation at low nanomolar concentrations, abrogate signal-
ling through the MAP/ Mitogen-Activated protein kinase Pathway and block 
proliferation of cells carrying BRAF with the V600E mutation. PLX4032 
therefore inhibits the growth and induces the progression in human mela-
noma tumours transplanted into immune-compromised mice.  
None of these effects are observed in normal tissue or in tumour cells that 
lack a BRAF mutation [5, 6]. 
2 Indication 
Vemurafenib is indicated for patients with BRAF V600E mutation positive 
advanced/metastatic unresectable melanoma as detected by an FDA-
approved test (cobas® 4800 BRAF V600 mutation test by Roche Molecular 
Systems) [7]. Vemurafenib is not recommended for use in patients with 
wild-type (i.e. unmutated) BRAF melanoma. 
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3 Current regulatory status 
Vemurafenib is currently not approved by the EMA, but was recommended 
by the Committee for Medicinal Products for Human Use (CHMP) of EMA 
for approval of first-in-class treatment for metastatic or unresectable mela-
noma  in December 2011 [8]. The approval is expected for February 2012 
[9]. 
Vemurafenib was approved by the FDA in August 2011 based on the (ongo-
ing) BRIM-3 study [10, 11] for the treatment of patients with unresectable or 
metastatic melanoma with the BRAFV600E mutation as detected by an 
FDA-approved test. 
4 Burden of disease 
Melanomas are malignant tumours of melanocytes. Suspicious lesions are 
nevi (i.e. moles or birthmarks) with, for example, variable discoloration, 
growth or development of satellites [12]. Risk factors for developing mela-
nomas include prior melanomas, a positive family history and multiple clin-
ically atypical moles/dysplastic nevi. In addition, genetic factors and sun 
exposure can contribute towards the development of melanomas [13]. To 
confirm the diagnosis of melanoma a biopsy, at best by local excision, should 
be performed [12]. Median age at diagnosis is 59 years [12]. 
Staging of melanomas based on the tumour, node, metastasis (TNM) system 
includes describing the spread, aggressiveness and the size of the tumour. By 
taking into account characteristics like thickness, ulcerations and the mi-
totic rate of the primary tumour, by assessing the spread to regional lymph-
nodes including satellite lesions (tumour cells separated from the primary 
tumour) and in-transit metastases and by evaluating distant metastases, pa-
tients are grouped into four prognostic categories (stage I –IV) [14]. Other 
factors which influence prognosis are gender, age and localisation of the tu-
mour where younger patients, women and patients with tumours on the ex-
tremities have a better prognosis [12]. For patients suffering from stage IV 
disease, sites of metastases and elevated lactate-dehydrogenase (LDH) levels 
are also associated with poor outcomes [13]. If the tumour has spread be-
yond near-by lymph-nodes, it is called advanced or metastatic melanoma 
which corresponds to stage IV disease. Metastases most often occur in the 
skin or in lymph-nodes, or in organs such as the lungs, the liver, the brain 
and in the bones. Staging is also an important factor for the determination of 
the most appropriate treatment [14].  
The majority of patients, about 85%, present with localised disease, corre-
sponding to 5-year survival rates of up to 90%. In about 13% the regional 
lymph nodes are affected at diagnosis, leading to diminished survival rates 
of 20%-70%. About 2%-5% of patients present with distant metastases that 
is stage IV. Long-term survival of all patients with distant metastases is less 
than 10% [13]. Median survival is 6 to 9 months [15]. 
approved by FDA  
Aug 2011,  
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risk factors for 
melanoma: positive 
family history, genetic 
factors, sun exposure…  
 
based on TNM system 
for staging, 4 prognostic 
groups are 
differentiated 
 
gender, age, LDH levels 
and localisation are 
important factors for 
prognosis  
 
metastatic melanoma: 
median survival of  
6 - 9 months 
 
LBI-HTA | 2012 5 
In Austria, the incidence of melanomas is about 15 newly diagnosed cas-
es/100,000 persons per year and is constantly rising [16]. In 2007, overall 
1,100 people were newly diagnosed with malignant melanoma in Austria. Of 
those, about 5% of the tumours were already disseminated, resulting in 
about 60 persons with advanced melanoma per year [15]. 
In 2008, the EU incidence rate (per 100,000) of skin melanoma was 14.0, be-
ing 13.5 among males and 14.5 among females (overall cumulative risk of 
0.93%). Mortality rate (per 100,000) was of 2.9, being 3.2 among males and 
2.5 among females [17]. 
Metastases develop in 10-15% of patients with cutaneous melanoma [18]. 
The frequency of BRAF mutations ranges from 36% to 45% in primary mel-
anomas and 42-55% in metastatic melanoma. More than 75 somatic muta-
tions in the BRAF gene have been identified in melanoma and all mutations 
at V600 (74-90% V600E; 16-29% V600K) in exon 15 constitutively activate 
BRAF [18]. For Austria this means 25-33 patients present with BRAF muta-
tions in metastatic melanoma each year.  
5 Current treatment 
Treatment of un-resectable stage III melanoma and of stage IV melanomas 
focuses on symptom palliation, on preventing the tumour to spread, to re-
duce or getting rid of metastases and to maintain or achieve an acceptable 
quality-of-life [13]. Thus, cure is rarely possible [14].  
Generally, metastatic melanoma is difficult to treat, because advanced mel-
anomas are refractory to most standard systemic therapies [12]. Accordingly, 
little consensus on the standard of care exists due to the low levels of activity 
of all available options. Therapy may involve: 
 Surgical excision is the primary treatment for early stage melanomas, 
but is also indicated for metastatic melanoma. Resection should be 
performed for limited metastatic melanoma (i.e. if the disease has 
spread only to one site or only to a limited number of sites). If the tu-
mour has spread to multiple sites such as the brain, the lungs, gastro-
intestinal tract or lymph-nodes, surgery may be used for symptom 
palliation.   
 Single-agent chemotherapy:  
 dacarbazine (DTIC), which is licensed in Austria for melanoma, is 
currently the most active chemotherapy and has often been used as 
standard comparator (as monotherapy) for new therapeutic regi-
mens [13]. However, only 10%-20% of patients respond to this 
treatment, showing mainly partial remissions with a median re-
sponse duration of 3-4 months [13]. DTIC  is used also in poly-
chemotherapy regimes, particularly those including Platinum. 
 fotemustine for the treatment of disseminated malignant mela-
noma, foremost if the tumour has spread to the brain [19]. 
 temozolomide (off-label) shows similar benefits like DTIC. Due to 
its ability to penetrate into the brain and other parts of the nervous 
about 60 patients/year 
diagnosed with 
advanced melanoma in 
Austria  
 
cure rarely possible  
 
treatment options: 
 
 
surgery 
 
chemotherapy  
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system, it is often used for the treatment of patients with brain me-
tastases [14].  
 Immunotherapy:  
 high-dose interleukin-2 (licensed in the US) has shown long-lasting 
effects including complete remissions, but only in the minority of 
patients. Because of its serious side-effects, it remains a treatment 
option for patients in good condition. 
 interferon-α is licensed for the adjuvant therapy of patients who are 
disease-free after surgery but who are at high risk of systemic re-
currence [14]. 
 ipilimumab, a monoclonal antibody targeting the CTLA-4, was re-
cently (2011) approved in Europe and has been added as an option 
for the second-line therapy of advanced melanoma [20]. 
 Radiation therapy either to metastases outside the brain for symptom 
palliation or as whole brain radiation therapy which can prolong sur-
vival, especially if the tumour outside the brain is controlled [14]. 
 Due to the low effectiveness of the available treatment options, all 
newly diagnosed patients with advanced melanoma should be consid-
ered for participating in clinical trials [12].  
To conclude: there is no standard treatment for advanced or metastatic mel-
anoma. The best choice is the inclusion into a clinical trial. Systemic treat-
ments actually used include dacarbazine, ipilimumab, temozolomide, vin-
blastine, fotemustine interleukin-2, interferons, taxanes, cisplatin or car-
boplatin. Different combinations are possible [21, 22]. According to the Eu-
ropean guidelines, dacarbazine represents the reference drug for the sys-
temic metastatic disease [22]. Non-resectable in-transit metastases or inop-
erable primary tumours of the limbs without additional metastases may be 
treated with isolated limb perfusion using e.g. melphalan and/or tumour ne-
crosis factor alfa [22]. In any case, radiation therapy can be an option, but 
evidence of its efficacy are lacking [21, 22]. 
6 Evidence 
Based on a literature search in Medline, EMBASE, DARE ( Database of the 
Centre for Review Dissemination of the National Institute of Health) and 
Cochrane Central, one phase II and one phase III trial was identified.  Both 
the phase III trial (i.e. the BRIM-3 study as interim analysis [23, 24]) and 
the phase II trial (the BRIM-2 study only as abstracts [25, 26]) are still ongo-
ing and are evaluating the efficacy and safety of vemurafenib in patients 
with advanced melanoma,    
 
 
 
immunotherapy   
 
and radiation therapy   
 
or clinical trials  
 
1 RCT-interim analysis 
1 phase II 
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6.1 Efficacy and safety - Phase III studies 
Table 1: Summary of efficacy  
Study title: Improved survival with Vemurafenib in melanoma with BRAF V600E mutation [23, 24, 27]  
Study identifier ClinicalTrials.gov Nr:NCT01006980, Roche BRIM-3 NO25026, EudraCT Nr: 2009-012293-12  
Phase III, randomised (1:1 ratio), multicentre (104 centres in 12 countries world-wide), open-
label, two-arm, active control 
Design 
Duration  Enrolment: Between Jan 2010 and Dec 2010 2107 pts screened for BRAF
V600 mutation, 675 pts actually enrolled 
Median follow-up at time of interim analysis (December 2010): I: 3.8 vs.
C: 2.3 [23], updated analysis: (March 2011) I 6.2 vs. 4.5 [27] 
Cut-off date for final analysis:  completion planned in May 2014 
Hypothesis Superiority 
Funding Hoffmann-La Roche 
Intervention Vemurafenib 960 mg twice daily, orally Treatment groups
Control Dacarbazine 1000 mg/ m2 of body surface area i.v. every 3 weeks 
Overall survival  
(co-primary out-
come) 
OS Time from randomization to death from any cause 
Progression-free  
survival 
(co-primary out-
come) 
PFS Time from randomization to documented disease progression or 
death according to RECIST version 1.1 [28] 
Best overall response 
rate 
BORR Total number of patients whose best overall response is complete 
response (CR) or partial response (PR), divided by the total num-
ber of patients in the group for which the BORR is estimated [28] 
Complete response CR Disappearance of all known disease  [28] 
Endpoints and
definitions 
Partial response PR At least a 30% decrease in the sum of 
diameters of target lesions, taking as reference the 
baseline sum diameters [28] 
 Response duration RD The interval (days) between the date of the earliest qualifying re-
sponse and the date of PD or death for any cause 
 Time to response  TTR Time from date of the first dose of study medication to first doc-
umentation of objective tumour response (CR or PR) 
 Quality of Life QoL Using FACT-M 
Results and analysis 
Analysis  
description 
Primary analysis: Intention-to-treat analysis of 672 pts, interim analysis 
Two-sided unstratified log-rank test to compare survival rates in the two study groups. Hazard 
ratios for treatment with vemurafenib, as compared with dacarbazine, were estimated with the 
use of unstratified Cox regression, event–time distributions were estimated using the Kaplan–
Meier method 
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Characteristics Median age (range) I: 56 yrs (21-86 yrs) vs. C: 52 yrs (17-86 yrs)  
males I: 59% vs. C: 54%  
white race I: 99% vs. C: 100%,  
ECOG: 0 I: 68% vs. C: 68%, ECOG 1 I: 32% vs. C:32%  
Disease stage: M1c I: 66% vs. C:65%, M1b I: 18% vs. C:19%, M1a I: 
10% vs. C: 12%, unresectable IIIC I: 6% vs. C: 4%  
LDH ≤ upper limit of the normal range I: 42% vs. C: 42% 
Inclusion Age: ≥18 years;  unresectable, previously untreated stage IIIC or stage 
IV melanoma, positive BRAF V600 mutation detected by the Roche 
investigational PCR-based Cobas 4800 BRAF V600 Mutation Test, life 
expectancy ≥3 months, ECOG PS 0 or 1; -adequate haematologic, he-
patic, and renal function, as defined by laboratory values within 28 
days prior to initiation of dosing  
Analysis  
population 
Exclusion Cancer history within the previous 5 years (except for basal- or squa-
mous-cell carcinoma of the skin or carcinoma of the cervix); CNS me-
tastases, unless such metastases had been definitively treated >3 
months previously with no progression and no requirement for con-
tinued glucocorticoid therapy; mean QTc interval ≥ 450 msec at 
screening; embolism 
Treatment group Control (Dacarbazine) Intervention (Vemurafenib) 
Number of subjects n = 338 n = 337 
OS (months)  
median/ interim [23] 
95% CI  
median/updated analysis 
[27], 95% CI 
 
6 months OS rate (%) 
95% CI 
 
7.8 
6.3 to 10.3 
7.9  
7.3 to 9.6 
 
64  
56 to 73 
 
9.2  
8.0 to not reached 
not reached  
9.6 to not reached 
 
84  
78 to 89 
Number of subjects n = 274 n = 275 
PFS (months)  
median 
95% CI 
 
6 months event-free 
rate (%) 
95% CI 
1.6  
1.6 to 1.7 
 
 
12 
7 to 18 
5.3 
4.9 to 6.6 
 
 
47  
38 to 55 
Number of subjects n = 220 n =219 
Descriptive  
statistics and  
estimated  
variability 
 
 
 
 
BORR (%) 
95% CI 
 
CR (n (%)) 
PR (n (%)) 
5.5  
2.8 to 9.3 
 
0 (0%) 
12 (5.5%) 
48.4  
41.6 to 55.2 
 
2 (0.9%) 
104 (47.5%) 
 Number of subjects n = 12 n = 106 
 RD (months) 
 median  
95% CI 
 
NR  
4.60 to NR 
 
5.5  
4.0 to 5.7 
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 TTR (months)  
median  
range 
 
2.7 
1.6 to 5.8 
 
1.5 
1.0 to 5.5 
 QoL - - 
Comparison groups  Intervention vs Control 
HR for death 
Interim 
updated analysis 
0.37 
0.44 
95%CI 
Interim 
updated analysis 
 
0.26 to 0.55 
0.33 to 0.59 
OS 
P value  
(interim and updated analysis) 
<0.001 
HR  
 
0.26 
95%CI 0.20;0.33 
PFS  
P value  <0.001 
Point estimate NR 
Variability NR 
BORR 
P value  <0.0001 
Point estimate NR 
Variability NR 
RD 
P value  NR 
Point estimate NR 
Variability NR 
Effect estimate 
per comparison 
TTR  
P value  NR 
Comment: Statistical plan revision: the original primary endpoint was OS only. After the interim analysis
(at >50% of total events), the statistical plan was revised, including PFS as a co-primary end-
point. 
Protocol revision: since the PFS endpoint met the statistical significance at the interim analysis,
the protocol was amended on 14/01/2011 to allow patients in dacarbazine arm to cross over to
vemurafenib. 
Abbreviations M1c = Metastases to other visceral sites with a normal serum LDH OR any metastasis associated with 
an elevated serum LDH, M1b = Lung metastases in patients with a normal serum LDH, M1a = Metastases 
to distant skin, subcutaneous, or lymph node sites, with a normal serum LDH, NR = not reported, ECOG PS 
– Eastern Cooperative Oncology Group performance status, HR = hazard ratio, CI= confidence interval. 
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Table 2: most frequent adverse events [23] 
Grade (according to CTC 
version 4.0) 
Outcome, n (%) 
Only <10% 
Control  
(Dacarbarzine) (n= 282) 
Intervention  
(Vemurafenib) (n=336) 
Grade 2 (only <10%) Arthralgia 1 (<1) 60 (18) 
 Rash 0 33 (10) 
 Fatigue 33 (12) 38 (11) 
 Nausea 32 (11) 25 (7) 
Grade 3 (only <5%) Cutaneous squamous –
cell carcinoma 
1 (<1) 40 (12) 
 Rash 0 28 (8) 
 Neutropenia 15 (5) 0 
Grade 4  Neutropenia 8 (3) 1 (<1) 
Grade 5 Neutropenia 1 (<1) 0 
All Grades Arthralgia 9 (3) 165 (49) 
 Rash 3 (1) 121 (36) 
 Alopecia 6 (2) 117 (35) 
 Photosensitivity  
reactions 
10 (4) 101 (30) 
 Nausea  115 (41) 101 (30) 
 Diarrhoea 34 (12) 84 (25) 
 Headache  26 (9) 72 (21) 
Patients with dose modi-
fication or interruption 
 
44 (16) 
 
129 (38) 
Other outcomes 
Patients interrupting only 12 (4,2) 34 (7,1) 
 
 
In the pivotal phase III, randomised, open-label on-going BRIM-3 study 
(NCT01006980) [10, 23, 24], 675 previously untreated patients (17-86 years) 
with stage IIIc-IV metastatic melanoma presenting the BRAF V600E muta-
tion were randomised to receive oral vemurafenib 960 mg twice daily or in-
travenous dacarbazine. The primary endpoints were overall survival (OS) 
and progression-free survival (PFS) in the intention to treat population. 
At the interim analysis median OS was 9.2 months in the vemurafenib group 
and 7.8 months in the control group, but these result were considered “unre-
liable” by the investigators due to the limited number of patients with long-
er periods of follow-up [24]. The OS rate also favoured patients treated with 
vemurafenib (I 84% vs C 64%) and risk of death was reduced by 63%. At the 
same time, the final analysis of PFS was performed which also showed im-
proved results for vemurafenib (HR = 0.26; 95% CI: 0.20; 0.33; p<0.0001) 
[23]. Due to these results the data and safety monitoring board recom-
mended that the protocol should be amended to allow patients to cross-over 
to the vemurafenib group. These changes were implemented in February 
2011.  
Nonetheless updated results for OS at a cut-off date of March 2011 are avail-
able [11] where median OS was not reached for vemurafenib (95% CI: 9.69; 
NR) but was 7.9 months (95% CI: 7.3; 9.6) for dacarbazine; the HR for death 
was with 0.44 (95% CI: 0.33; 0.59; p<0.0001) similar to that of the interim 
analysis.  
BRIM-3: 675 pts 
untreated,  
OS and PFS as primary 
endpoints 
interim analysis: 
PFS 5.3 vs. 1.6 3 months 
in favour of 
vemurafenib 
BORR: I: 48% vs .C: 5% 
CR only in 1% (I) 
 
only 
immature/unreliable 
data for OS due to lack 
of follow-up, 
since cross-over: no  
”mature” OS data 
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48% vs 5% in the vemurafenib vs. dacarbazine showed confirmed objective 
responses. BORR in the vemurafenib groups was mainly due to partial re-
sponses, since complete responses were achieved in only 2 patients (i.e. 1%), 
whereas the majority that is 104 (48%) experienced partial responses. The 
median time to response was 1.5 months (vemurafenib) vs. 2.7 months 
(dacarbazine). 
The most frequent adverse events (AEs) at the interim analysis were cutane-
ous events (rash, photosensitivity skin reactions), arthralgia, alopecia, nau-
sea, vomiting, diarrhoea and headache. The most frequent grade 3 AE was 
squamous skin cell carcinoma (I 12% vs. C <1%) [23]. 
Overall, drug related AEs were observed in 94% in the vemurafenib group 
and in 69% in the dacarbazine group respectively [24]. Similarly, serious 
AEs were more frequent in the intervention group than in the control group 
(I 33% vs C 16%). Serious AEs which were classified as drug-related oc-
curred in I 26% vs C 5%, consequently leading to dose modification or inter-
ruption in 129 of 336 patients (38%) in the vemurafenib group and in 44 of 
282 patients (16%) in the dacarbazine group of which the majority were 
drug modifications [23]. Permanent discontinuation was observed in 6% 
vemurafenib group vs. 4% in the dacarbazine group [27]. 66 patients died 
overall in the dacarbazine group and 42 in the vemurafenib group, but the 
main cause of death was disease progression. Deaths due to other causes oc-
curred in 17% in the vemurafenib group and in 5% in the dacarbazine 
group. 
The BRIM-3 trial is ongoing. More publications are to be expected.  
6.2 Efficacy and safety - further studies 
In the on-going phase II, single-arm BRIM-2 trial, is published as prelimi-
nary results, [25, 26]) only: 132 previously treated patients received oral V 
960 mg, twice daily. After a median follow-up of 7 months, the best overall 
response rate (primary endpoint) was of 52.3% (95% CI 43; 61%): complete 
response rate was 2.3%. Median duration of response and median PFS were 
of 6.8 and 6.2 months, respectively. 
The most common grade 3 AE was cutaneous squamous cell carcinoma 
(24.2%), the majority centrally reviewed as keratoacanthoma-type. AEs were 
generally reversible with dose modification or interruption. 42% of pts re-
quired dose reductions, most commonly for rash, arthralgia and LFT ab-
normalities. 
7 Estimated costs 
The costs of ipilimumab have not been determined yet in Austria. As 
vemurafenib is indicated as treatment of BRAF-mutated ad-
vanced/metastatic melanoma only, the companion genetic mutation test 
costs of about 120 € have to be taken into consideration for all ad-
vanced/metastatic melanoma patients. 
AE-induced 
modification or 
interruption: 7% vs. 4% 
in favour of dacarbazine  
BRIM 2: only as 
abstract, 132 pre-treated 
pts 
RR primary endpoint: 
52% 
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The monthly costs for Zelboraf™ 240 mg 56 film tablets, with a recom-
mended daily dose of twice 960 mg, is estimated to range between 7.200 
€ [29] and 12.620 € [30].  
On the duration of the therapy nothing is said in the published data. 
Nevertheless, 6 months (time from representation till death) and more 
might be calculated (range 43.200 € to 75.900 €). 
8 On-going research 
NCT01307397: An open-label, multicentre expanded access study of 
RO5185426 in patients with metastatic melanoma. Phase III, open-label, 
non-randomised, single-arm. 900 patients (planned).  
Other active comparators in development  
 Dabrafenib (originator: GSK), oral. A phase III, randomised, 
open-label, dacarbazine-controlled trial (NCT01227889) in 200 pa-
tients with previously untreated advanced (unresectable stage III) 
or metastatic (stage IV) melanoma that is BRAF mutation positive 
(V600E) was initiated in January 2011. Primary endpoint is PFS. 
Final results are expected at the end of 2012.  
 Trametinib (originator: Japan Tabacco; licensee: GSK), oral. A 
phase III, randomised, open-label, crossover, chemotherapy-
controlled trial (NCT01245062) is ongoing in 322 patients with 
previously untreated advanced (unresectable stage III) or metas-
tatic (stage IV) melanoma that is BRAF mutation positive 
(V600E). Primary endpoint is PFS. Final results are expected at 
the end of 2012.  
 Masitinib (originator: AB Science), oral. A phase III, open-label, 
dacarbazine-controlled trial (NCT01280565) was initiated in Jan-
uary 2011 in 200 (planned) patients with non-resectable or metas-
tatic stage III or stage IV melanoma carrying a mutation in the 
juxta membrane domain of c-kit. Primary endpoint is PFS. Pri-
mary results are expected in December 2013. 
 Talminogene laherparepvec (originator: Amgen), intratumoral. It 
is an oncolytic Herpes Simplex Virus encoding human granulo-
cyte macrophage-colony stimulating factor (GM-CSF) A phase III, 
randomised, open-label, GM-CSF-controlled trial (NCT00769704) 
is currently ongoing in 430 patients with stage IIIb, IIIc or stage 
IV unresectable melanoma. Primary endpoint is durable response 
rate and the estimated study completion date is June 2012. 
 Velimogene (originator: Vical), intratumoral. A phase III, random-
ised, open-label, controlled (vs. dacarbazine or temozolamide) trial 
(NCT00395070) is currently ongoing in 390 patients with previ-
ously untreated stage III or IV recurrent metastatic melanoma. Es-
timated study completion date is June 2012. 
estimated monthly 
costs:  
7.200 - 12.620 €   
 
Dabrafenib (originator: 
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9 Commentary  
Metastatic melanoma has a poor prognosis with a median survival for pa-
tients with stage IV melanoma ranging from 6 to 9 months and a 3-year sur-
vival rate of only 10-15% [1, 31]. Generally, metastatic melanoma is difficult 
to treat, because advanced melanomas are refractory to most standard sys-
temic therapies and therapeutic options are limited [12]. Even though 
dacarbazine was considered as standard therapy for the treatment of sys-
temic metastatic disease, response rates are low (7-12% of patients) [23]. Ac-
cordingly, little consensus on the standard of care exists and participation in 
clinical trials is highly recommended [4]. However, in 2011, ipilimumab, a 
new drug, was licensed in both Europe and the U.S. for the treatment of ad-
vanced/metastatic melanoma. 
In addition, the FDA approved vemurafenib in August 2011 based on the in-
terim results of an open-label phase III trial, the BRIM-3 study [23, 24, 27] 
which investigated the drug for unresectable advanced/ metastatic mela-
noma in previously untreated patients in comparison to dacarbazine. Im-
proved results for PFS (i.e. 3.7 months gain in PFS for patients treated with 
vemurafenib), as well as for OS were found. Due to the fact that median OS 
was not yet reached at the time of the last analysis, the FDA expects the 
market applicant to submit further updated results from the on-going trial 
with a minimum follow-up of 24 months after the last patient was enrolled 
into the trial [32]. Due to more favourable results for the vemurafenib group 
in an interim analysis, the study protocol was amended in February 2011 al-
lowing patients to cross-over to vemurafenib, thus any further OS results 
will be compromised. Since PFS “has not been demonstrated as a reliable 
surrogate for clinical benefit in this disease setting as both clinical trials in-
volving ipilimumab demonstrated an overall survival benefit in the absence 
of PFS benefit” [27], only mature OS data of “a clinically significant magni-
tude” would “represent direct evidence of clinical benefit” [27].  
In Europe, vemurafenib is currently not yet approved by the EMA, but the 
Committee for Medicinal Products for Human Use (CHMP) adopted a 
positive opinion, recommending approval as first-in-class treatment for me-
tastatic or unresectable melanoma in December 2011 [8]. The approval is 
expected for February 2012. It will be of interest, if the EMA will adopt a 
more narrow indication than the FDA, in terms of restricting therapy with 
vemurafenib to the first-line setting. Even though the BRIM-3 trial had en-
rolled only untreated patients, this is not reflected in the label approved in 
the U.S. Differences between the two agencies also occurred for ipilimumab, 
which was licensed for previously treated patients in Europe [33] and for 
unresectable or metastatic melanoma without further restrictions in the U.S. 
[34]. It is therefore unknown what the optimal sequencing of these therapies 
is and how efficacious ipilimumab would be in patients pretreated with ve-
murafenib. Recent trial results report that a combination therapy of 
ipilimumab with dacarbazine showed an OS benefit of 2.1 months, but with 
56.3% Grade 3 or 4 AE [35].  
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Even though the underlying mechanisms are not well understood yet [36], 
resistance to vemurafenib eventually develops and patients relapse despite 
initial response. “Most concerning is the non-clinical data suggesting that 
treatment with vemurafenib and other B-Raf inhibitors in the setting of a 
RAS mutation is pro-proliferative”…… A post-hoc exploratory analysis was 
conducted in which patients who had a reduction in target lesion size but 
had a progressive event with a new lesion were identified and overall sur-
vival was compared to those patients who had progressive disease with no 
evidence of tumour response. Conceivably, the tumours of those patients 
who developed new lesions in the setting of their target lesions decreasing in 
size developed an acquired resistance to therapy while the tumours of those 
patients who did not have a response had a primary resistance to therapy. It 
is interesting to see that there is no difference in survival for the two groups, 
suggesting that the patients who had an initial response in their target le-
sions did not have a survival benefit compared to the patients who were 
primarily resistant to the tumour” [27]. 
It might thus be the case, that by exploring these mechanisms improved out-
comes with vemurafenib therapy are possible. To mitigate the problem of re-
sistance, a combination of therapies is also suggested [36], which would in-
crease costs and potentially adverse events too. The choice of which combi-
nation of agents to use in any given situation remains to be determined and 
represents a challenge to the field [4], foremost since several other therapies 
(e.g. dabrafenib, trametinib, masitinib, talminogene laherparepvec, velimo-
gene) all targeting mutation-specific melanoma are in development [4].  
Another issue concerns the selection of patients eligible for vermurafenib 
therapy. In the BRIM-3 trial, inclusion was tied to BRAF mutation detected 
with the Roche investigational Cobas 4800 BRAF V600 Mutation Test. Since 
the test used to detect the V600 mutations demonstrated to be specific for 
the V600E mutation, the FDA has consequently approved vemurafenib for 
patients with that mutation only. Control sequencing (Sanger method, refer-
ence standard) of BRAF V600 data were available for 542 patients (214 from 
phase III; 328 from phase II): V600K mutation was found in 40 patients 
only, 26 of whom were positive to the Cobas test (BRAF V600E) and 14 were 
not. Other mutations were not detected by the test [7]. Even though patients 
were selected using the Cobas Test, further characteristics or markers might 
be discovered which allow identification of patients with a higher potential 
to benefit.   
Finally about one third of the patients treated with vemurafenib develop – 
as a side effect – squamous cell carcinoma of the skin. Other frequent AE 
are: Arthralgia, rash and alopecia. The rapid appearance of these cutaneous 
squamous cell carcinoma may result from a shared risk factor with mela-
noma, the ultraviolet light exposure. This second cancer indicates a need for 
additional monitoring to survey patients with specific risk factors for this 
secondary cancer (e.g. smoking, alcohol, family history etc.) [37, 38]. Al-
though the response rates are higher with vemurafenib, the toxicity is con-
siderably higher compared to dacarbazin. Special attention is needed to ad-
dress the described cutaneous squamous cell carcinoma. 
No data and information is available on quality of life. 
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